Chemotherapy-induced neuropathy is a common, dose-dependent adverse effect of several
antineoplastics. It can lead to detrimental dose reductions and discontinuation of treatment …

Purpose To provide evidence-based guidance on the optimum prevention and treatment
approaches in the management of chemotherapy-induced peripheral neuropathies (CIPN) …

Peripheral neuropathy is one of the most common side effects of chemotherapy, affecting up
to 60% of all cancer patients receiving chemotherapy. Moreover, paclitaxel induces …

With a 3‐fold increase in the number of cancer survivors noted since the 1970s, there are
now over 28 million cancer survivors worldwide. Accordingly, there is a heightened …

Neurotoxic anticancer drugs, such as platinum-based anticancer drugs, taxanes, vinca
alkaloids, and proteasome/angiogenesis inhibitors are responsible for chemotherapy …

Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with
chemotherapy, but researchers rarely study its risk factors, fall risk, and prevalence in long …

Background Chemotherapy‐induced peripheral neuropathy (CIPN) is one of the most
debilitating long‐term side effects in breast cancer survivors. We conducted a randomized …

Taxane‐derived drugs are antineoplastic agents used for the treatment of highly common
malignancies. Paclitaxel and docetaxel are the most commonly used taxanes; however …

Background This study evaluates persistence and severity of docetaxel-induced neuropathy
(peripheral neuropathy (PN)) and impact on health related quality of life in survivors from …

Background: Paclitaxel-induced peripheral neuropathy (PN) is a serious clinical problem
with no approved drug for prevention. This study aimed to examine the neuroprotective …